CINtec PLUS and cobas HPV testing for triaging Canadian women referred to colposcopy with a history of low-grade squamous intraepithelial lesion: Baseline findings.
Adult
Aged
Cervix Uteri
/ pathology
Colposcopy
/ statistics & numerical data
DNA, Viral
/ genetics
Female
Humans
Middle Aged
Molecular Diagnostic Techniques
/ standards
Ontario
Papillomaviridae
/ genetics
Papillomavirus Infections
/ diagnosis
Prospective Studies
Reagent Kits, Diagnostic
/ standards
Sensitivity and Specificity
Squamous Intraepithelial Lesions
/ diagnosis
Uterine Cervical Neoplasms
/ virology
Young Adult
Uterine Cervical Dysplasia
/ diagnosis
CINtec PLUS test
Human papillomavirus (HPV) triage
Low-grade squamous intraepithelial lesion (LSIL) triage
cobas HPV test
p16/Ki-67 dual-stain cytology
Journal
Papillomavirus research (Amsterdam, Netherlands)
ISSN: 2405-8521
Titre abrégé: Papillomavirus Res
Pays: Netherlands
ID NLM: 101662552
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
04
04
2020
revised:
10
08
2020
accepted:
18
08
2020
pubmed:
24
8
2020
medline:
28
8
2021
entrez:
24
8
2020
Statut:
ppublish
Résumé
CINtec PLUS and cobas HPV tests were assessed for triaging women referred to colposcopy with a history of LSIL cytology. Both tests were performed at baseline using ThinPrep cervical specimens and biopsy confirmed cervical intraepithelial neoplasia grade 2 or worse (CIN2+) served as the clinical endpoint. In all ages, (19-76 years, n = 600), 44.3% (266/600) tested CINtec PLUS positive vs. 55.2% (331/600) HPV positive (p = 0.000). Based on 224 having biopsies, sensitivity to detect CIN2+ (n = 54) was 81.5% (44/54) for CINtec PLUS vs. 94.4% (51/54) for HPV testing (p = 0.039); specificities were, 52.4% (89/170) vs. 44.1% (75/170), respectively (p = 0.129). In women ≥30 years (n = 386), 41.2% (159/386) tested CINtec PLUS positive vs. 50.8% (196/386) HPV positive (p = 0.008). Based on 135 having biopsies, sensitivity to detect CIN2+ (n = 24) was 95.8% (23/24) for both CINtec PLUS and HPV tests; specificities were, 55.0% (61/111) vs. 50.5% (56/111), respectively (p = 0.503). For women referred to colposcopy with a history of LSIL cytology, CINtec PLUS or cobas HPV test could serve as a predictor of CIN2+ with high sensitivity, particularly in women ≥30 years. Either test can significantly reduce the number of women requiring further investigations and follow up in colposcopy clinics.
Identifiants
pubmed: 32828968
pii: S2405-8521(20)30044-6
doi: 10.1016/j.pvr.2020.100206
pmc: PMC7548977
pii:
doi:
Substances chimiques
DNA, Viral
0
Reagent Kits, Diagnostic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100206Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Références
Am J Obstet Gynecol. 2007 Oct;197(4):356.e1-6
pubmed: 17904958
J Cancer Res Ther. 2018 Sep;14(Supplement):S587-S593
pubmed: 30249873
Cytopathology. 2016 Aug;27(4):269-76
pubmed: 26932360
Am J Obstet Gynecol. 2013 Mar;208(3):184.e1-184.e11
pubmed: 23174289
J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9
pubmed: 16030305
Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:275-280
pubmed: 28086168
Cancer Cytopathol. 2015 Jun;123(6):373-81
pubmed: 25891096
Eur J Obstet Gynecol Reprod Biol. 2017 May;212:171-181
pubmed: 28081908
Gynecol Oncol. 2015 Feb;136(2):189-97
pubmed: 25579108
J Natl Cancer Inst. 2013 Oct 16;105(20):1550-7
pubmed: 24096620
Cancer Manag Res. 2019 Feb 22;11:1817-1827
pubmed: 30863187
Cancer Cytopathol. 2019 Mar;127(3):169-180
pubmed: 30811902
Ann Intern Med. 2017 Jan 17;166(2):118-127
pubmed: 27842420
J Cancer. 2019 Jun 2;10(12):2654-2660
pubmed: 31258773
J Natl Cancer Inst. 2001 Feb 21;93(4):293-9
pubmed: 11181776
J Cell Mol Med. 2009 Apr;13(4):648-59
pubmed: 19166485
J Clin Microbiol. 2012 Jun;50(6):1927-35
pubmed: 22518869
Int J Cancer. 2013 Feb 15;132(4):959-66
pubmed: 22806936
BMJ. 2018 Feb 27;360:k499
pubmed: 29487049
Am J Obstet Gynecol. 2003 Jun;188(6):1393-400
pubmed: 12824968
Diagn Cytopathol. 2013 Sep;41(9):767-75
pubmed: 23341349
Am J Obstet Gynecol. 2012 Jan;206(1):46.e1-46.e11
pubmed: 21944226
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Int J Cancer. 2012 Nov 15;131(10):2349-59
pubmed: 22323075
Gynecol Oncol. 2015 Feb;136(2):178-82
pubmed: 25579107
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
Cancer Cytopathol. 2011 Jun 25;119(3):158-66
pubmed: 21442767
Br J Cancer. 2011 Sep 27;105(7):877-80
pubmed: 21952649